A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Clinical Trials—Real-World Data to Build a Future for Our Patients In the article that accompanies this editorial, Kwak et al 6 demonstrate using individual patient data from randomized trials that ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

DEAR DR. ROACH: I am a 74-year-old male in relatively good health. The only prescribed medication I take is 5 mg of amlodipine daily. My issue is my PSA score. In 2004, I had a UTI, and the urologist ...

New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MENLO PARK, Calif., Nov. 20, 2025 /PRNewswire/ -- MyOme, ...